These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 28321512

  • 21. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM, Li W, Jiang XL.
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [Abstract] [Full Text] [Related]

  • 22. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB.
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [Abstract] [Full Text] [Related]

  • 23. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L.
    Lancet; 2021 Jun 19; 397(10292):2372-2384. PubMed ID: 34090625
    [Abstract] [Full Text] [Related]

  • 24. SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.
    Stodtmann S, Chen MJ, Ponce-Bobadilla AV, Finney-Hayward TK, Kalabic J, Mostafa NM.
    Clin Pharmacol Drug Dev; 2024 Sep 19; 13(9):1033-1043. PubMed ID: 38953600
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A.
    Inflamm Bowel Dis; 2017 Mar 19; 23(3):453-460. PubMed ID: 28129288
    [Abstract] [Full Text] [Related]

  • 32. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.
    Burness CB, Keating GM.
    BioDrugs; 2013 Jun 19; 27(3):247-62. PubMed ID: 23580096
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R.
    United European Gastroenterol J; 2020 Dec 19; 8(10):1186-1195. PubMed ID: 33028169
    [Abstract] [Full Text] [Related]

  • 34. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R.
    Lancet; 2022 Jun 04; 399(10341):2113-2128. PubMed ID: 35644166
    [Abstract] [Full Text] [Related]

  • 35. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C.
    J Crohns Colitis; 2018 Aug 29; 12(9):1053-1066. PubMed ID: 29917070
    [Abstract] [Full Text] [Related]

  • 36. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S, GARDENIA Study Group.
    Lancet Gastroenterol Hepatol; 2022 Feb 29; 7(2):118-127. PubMed ID: 34798038
    [Abstract] [Full Text] [Related]

  • 37. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
    Zacharias P, Damião AOMC, Moraes AC, Teixeira FV, Ludvig JC, Nones RB, Saad-Hossne R, Sassaki LY, Silva RPLD, Facchin L, Olandoski M, Kotze PG.
    Arq Gastroenterol; 2017 Dec 29; 54(4):321-327. PubMed ID: 28977114
    [Abstract] [Full Text] [Related]

  • 38. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P, PURSUIT-SC Study Group.
    Gastroenterology; 2014 Jan 29; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P, Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU)..
    J Gastroenterol; 2017 Jul 29; 52(7):788-799. PubMed ID: 27722996
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S, Sanchez Gonzalez Y, Hébuterne X, Lindsay JO, Higgins PDR, Cao Q, Nakase H, Colombel JF, Loftus EV, Panaccione R.
    Lancet Gastroenterol Hepatol; 2023 Nov 29; 8(11):976-989. PubMed ID: 37683686
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.